165K-Patient Study: No Safe Group for Risperidone
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Dr. Byron Creese and Brunel University London researchers analyzed anonymized NHS records from 2004–2023 covering more than 165,000 dementia patients and found risperidone increased stroke risk uniformly across all patient groups, challenging the assumption that some patients are safer candidates.
- The British Journal of Psychiatry published the matched cohort study, which found stroke rates of 22.2 per 1,000 person-years among prior-stroke patients on risperidone versus 17.7 not on the drug, and 2.9% versus 2.2% among those with no prior stroke.
- Risperidone is currently the only antipsychotic licensed in the UK for dementia-related agitation, leaving physicians with no pharmacologic alternative when behavioral therapies fail to manage severe distress.
- NHS guidance recommends limiting risperidone to six weeks for severe symptoms, but the study found many patients stay on the drug longer and there is still no dementia-specific guidance on how to monitor for stroke risk.
- Dr. Creese noted that stroke risk was higher among patients using the medication for shorter periods (12 weeks) than for longer durations, and called for the data to inform updated, person-centered prescribing guidance.
Why it matters: With no licensed alternative for dementia-related agitation in the UK, doctors prescribing risperidone now face evidence that no patient subgroup is risk-free—forcing harder informed-consent conversations and likely prompting calls to update NHS prescribing and monitoring guidance for the country's roughly half of dementia patients who experience severe agitation.
